Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), Insmed (INSM – Research Report) and BioNTech SE (BNTX – Research Report).
Cartesian Therapeutics (RNAC)
In a report released today, Thomas Smith from Leerink Partners initiated coverage with a Buy rating on Cartesian Therapeutics and a price target of $39.00. The company’s shares closed last Monday at $18.26.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Cartesian Therapeutics is a Strong Buy with an average price target of $45.00, representing a 152.8% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $54.00 price target.
See the top stocks recommended by analysts >>
Insmed (INSM)
Insmed received a Buy rating and a $48.00 price target from Truist Financial analyst Nicole Germino today. The company’s shares closed last Monday at $24.11.
According to TipRanks.com, Germino is ranked #433 out of 8792 analysts.
Insmed has an analyst consensus of Strong Buy, with a price target consensus of $46.50, implying a 90.8% upside from current levels. In a report issued on April 11, Barclays also maintained a Buy rating on the stock with a $40.00 price target.
BioNTech SE (BNTX)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on BioNTech SE, with a price target of $95.00. The company’s shares closed last Monday at $88.01, close to its 52-week low of $85.21.
According to TipRanks.com, Papadakis is a 5-star analyst with an average return of
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $111.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNAC:
- Cartesian Therapeutics: Capital Structure Updates and Conference Insights
- Selecta Biosciences Inc trading halted, news pending
- Cartesian announces new employment inducement grants
- Cartesian Therapeutics Bolsters Executive Team with Key Appointments
- Cartesian Therapeutics’ Strategic Stock Reorganization Wins Approval
